FARN vs. ERGO, SLN, PRTC, OXB, HZD, VRP, ARIX, AVCT, 4BB, and BVXP
Should you be buying Faron Pharmaceuticals Oy stock or one of its competitors? The main competitors of Faron Pharmaceuticals Oy include Ergomed (ERGO), Silence Therapeutics (SLN), PureTech Health (PRTC), Oxford Biomedica (OXB), Horizon Discovery Group plc (HZD.L) (HZD), Verona Pharma plc (VRP.L) (VRP), Arix Bioscience (ARIX), Avacta Group (AVCT), 4basebio (4BB), and Bioventix (BVXP). These companies are all part of the "biotechnology" industry.
Faron Pharmaceuticals Oy vs.
Ergomed (LON:ERGO) and Faron Pharmaceuticals Oy (LON:FARN) are both small-cap medical companies, but which is the superior business? We will compare the two businesses based on the strength of their community ranking, valuation, earnings, dividends, risk, media sentiment, profitability, analyst recommendations and institutional ownership.
Ergomed has a net margin of 9.87% compared to Faron Pharmaceuticals Oy's net margin of 0.00%. Ergomed's return on equity of 18.08% beat Faron Pharmaceuticals Oy's return on equity.
In the previous week, Faron Pharmaceuticals Oy had 2 more articles in the media than Ergomed. MarketBeat recorded 2 mentions for Faron Pharmaceuticals Oy and 0 mentions for Ergomed. Faron Pharmaceuticals Oy's average media sentiment score of 0.41 beat Ergomed's score of 0.00 indicating that Faron Pharmaceuticals Oy is being referred to more favorably in the news media.
Faron Pharmaceuticals Oy received 75 more outperform votes than Ergomed when rated by MarketBeat users. Likewise, 77.51% of users gave Faron Pharmaceuticals Oy an outperform vote while only 75.63% of users gave Ergomed an outperform vote.
Ergomed has higher revenue and earnings than Faron Pharmaceuticals Oy. Faron Pharmaceuticals Oy is trading at a lower price-to-earnings ratio than Ergomed, indicating that it is currently the more affordable of the two stocks.
Ergomed has a beta of 0.79, indicating that its share price is 21% less volatile than the S&P 500. Comparatively, Faron Pharmaceuticals Oy has a beta of 0.36, indicating that its share price is 64% less volatile than the S&P 500.
71.1% of Ergomed shares are held by institutional investors. Comparatively, 10.7% of Faron Pharmaceuticals Oy shares are held by institutional investors. 18.2% of Ergomed shares are held by company insiders. Comparatively, 31.8% of Faron Pharmaceuticals Oy shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.
Summary
Ergomed beats Faron Pharmaceuticals Oy on 9 of the 14 factors compared between the two stocks.
Get Faron Pharmaceuticals Oy News Delivered to You Automatically
Sign up to receive the latest news and ratings for FARN and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of LON and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Faron Pharmaceuticals Oy Competitors List
Related Companies and Tools
This page (LON:FARN) was last updated on 3/25/2025 by MarketBeat.com Staff
Buy FARN Stock Free FARN Stock Alerts